Sirona Biochem Corp.  

(Public, CVE:SBM)   Watch this stock  
Find more results for cve:sbm
0.120
+0.005 (4.35%)
Delayed:   10:26AM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.12 - 0.12
52 week 0.03 - 0.15
Open 0.12
Vol / Avg. 11,500.00/270,971.00
Mkt cap 9.56M
P/E     -
Div/yield     -
EPS -0.05
Shares 79.67M
Beta -0.10
Inst. own     -

Key stats and ratios

Q3 (Jul '12) 2011
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -43.93% -114.01%
Return on average equity -57.52% -147.86%
Carbon Disclosure Rating - -

Address

955-789 West Pender St.
VANCOUVER, BC V6C 1H2
Canada
+1-604-6414466 (Phone)
+1-604-6085471 (Fax)

Website links

External links

Discussion Group - Google Finance

Description

Sirona Biochem Corp. is a Canada-based, development-stage company. The Company is engaged in the discovery and development of drug compounds with a focus on treatments for Type II Diabetes and Obesity. It is specializes in the development of carbohydrate-based molecules. It is also focused on advancing three programs: therapeutics, cosmetic agents and biological ingredients. The Company�s wholly owned subsidiary, TFCHEM S.A.R.L (TFC), has developed a platform technology based upon fluorinated sugar mimics for the treatment of diabetes and obesity. TFC focuses on carrying out a two year research program to develop a chemical process to achieve the synthesis of a new class of Sodium Glucose Co-transporter Inhibitors for the treatment of Type II Diabetes and Obesity. On March 31, 2011, the Company completed the acquisition of TFCHEM S.A.R.L (TFC).

Officers and directors

Howard Verrico Chairman of the Board, Interim President, Secretary
Neil Belenkie Chief Executive Officer
Christopher D. Hopton Chief Financial Officer, Director
Sean Cunliffe Chief Business Officer
Age: 54
Geraldine Deliencourt-Godefroy Independent Director
Alex Marazzi Independent Director
Michael Rogers Independent Director
Christopher R. Verrico Independent Director